Amphotericin-B and Voriconazole for Pulmonary Blastomycosis
Status:
Terminated
Trial end date:
2020-09-25
Target enrollment:
Participant gender:
Summary
All patients with pulmonary blastomycosis requiring mechanical ventilation will have their
blood concentrations measured for the antifungal drugs, amphotericin-B and voriconazole; as
well as an analysis of the susceptibility of their infecting species of blastomyces. This
information will then be analyzed relative to their rate of clinical recovery from this
serious fungal infection.
Phase:
Phase 4
Details
Lead Sponsor:
University of Manitoba
Collaborator:
Pfizer
Treatments:
Amphotericin B Liposomal amphotericin B Voriconazole